ERBB2 and breast carcinoma: T-DM1 was approved for use in advanced HER2-positive breast cancer in 2013 based on the results of the EMILIA trial [24], and following the results of the KATHERINE trial, the use has been extended to HER2-positive early breast cancer cases with residual disease post-neoadjuvant chemotherapy [25].